Cargando…
First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
INTRODUCTION: Acquired severe aplastic anemia (SAA) is a rare and progressive disease characterized by an immune-mediated functional impairment of hematopoietic stem cells. Transplantation of these cells is a first-line treatment option if HLA-matched related donors are available. First-line immunos...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081818/ https://www.ncbi.nlm.nih.gov/pubmed/21541024 http://dx.doi.org/10.1371/journal.pone.0018572 |
_version_ | 1782202239088066560 |
---|---|
author | Peinemann, Frank Grouven, Ulrich Kröger, Nicolaus Bartel, Carmen Pittler, Max H. Lange, Stefan |
author_facet | Peinemann, Frank Grouven, Ulrich Kröger, Nicolaus Bartel, Carmen Pittler, Max H. Lange, Stefan |
author_sort | Peinemann, Frank |
collection | PubMed |
description | INTRODUCTION: Acquired severe aplastic anemia (SAA) is a rare and progressive disease characterized by an immune-mediated functional impairment of hematopoietic stem cells. Transplantation of these cells is a first-line treatment option if HLA-matched related donors are available. First-line immunosuppressive therapy may be offered as alternative. The aim was to compare the outcome of these patients in controlled trials. METHODS: A systematic search was performed in the bibliographic databases MEDLINE, EMBASE, and The Cochrane Library. To show an overview of various outcomes by treatment group we conducted a meta-analysis on overall survival. We evaluated whether studies reported statistically significant factors for improved survival. RESULTS: 26 non-randomized controlled trials (7,955 patients enrolled from 1970 to 2001) were identified. We did not identify any RCTs. Risk of bias was high except in 4 studies. Young age and recent year of treatment were identified as factors for improved survival in the HSCT group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the IST group. In 19 studies (4,855 patients), summary statistics were sufficient to be included in meta-analysis. Considerable heterogeneity did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies. CONCLUSIONS: Young age and recent year of treatment were identified as factors for improved survival in the transplant group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the immunosuppressive group. Considerable heterogeneity of non-randomized controlled studies did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies. |
format | Text |
id | pubmed-3081818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30818182011-05-03 First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia Peinemann, Frank Grouven, Ulrich Kröger, Nicolaus Bartel, Carmen Pittler, Max H. Lange, Stefan PLoS One Research Article INTRODUCTION: Acquired severe aplastic anemia (SAA) is a rare and progressive disease characterized by an immune-mediated functional impairment of hematopoietic stem cells. Transplantation of these cells is a first-line treatment option if HLA-matched related donors are available. First-line immunosuppressive therapy may be offered as alternative. The aim was to compare the outcome of these patients in controlled trials. METHODS: A systematic search was performed in the bibliographic databases MEDLINE, EMBASE, and The Cochrane Library. To show an overview of various outcomes by treatment group we conducted a meta-analysis on overall survival. We evaluated whether studies reported statistically significant factors for improved survival. RESULTS: 26 non-randomized controlled trials (7,955 patients enrolled from 1970 to 2001) were identified. We did not identify any RCTs. Risk of bias was high except in 4 studies. Young age and recent year of treatment were identified as factors for improved survival in the HSCT group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the IST group. In 19 studies (4,855 patients), summary statistics were sufficient to be included in meta-analysis. Considerable heterogeneity did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies. CONCLUSIONS: Young age and recent year of treatment were identified as factors for improved survival in the transplant group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the immunosuppressive group. Considerable heterogeneity of non-randomized controlled studies did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies. Public Library of Science 2011-04-25 /pmc/articles/PMC3081818/ /pubmed/21541024 http://dx.doi.org/10.1371/journal.pone.0018572 Text en Peinemann et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Peinemann, Frank Grouven, Ulrich Kröger, Nicolaus Bartel, Carmen Pittler, Max H. Lange, Stefan First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia |
title | First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia |
title_full | First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia |
title_fullStr | First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia |
title_full_unstemmed | First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia |
title_short | First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia |
title_sort | first-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081818/ https://www.ncbi.nlm.nih.gov/pubmed/21541024 http://dx.doi.org/10.1371/journal.pone.0018572 |
work_keys_str_mv | AT peinemannfrank firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia AT grouvenulrich firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia AT krogernicolaus firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia AT bartelcarmen firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia AT pittlermaxh firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia AT langestefan firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia |